Pipelines

© Getty Images

Cancer vaccine shows promising long-term survival data

By Isabel Cameron

Ultimovacs, a clinical-stage biotech developing novel immunotherapeutic cancer vaccines, has announced ‘encouraging’ overall survival (OS) data for its phase 1 clinical trial in malignant melanoma.

© Getty Images

Kuano raises £1.8 million to accelerate quantum drug discovery

By Isabel Cameron

Kuano, a drug discovery company combining quantum mechanics with AI, has announced the close of its £1.8 million seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other...

© Getty Images

New treatment for Fabry disease receives key recommendation

By Isabel Cameron

Chiesi, the biopharmaceutical and healthcare group, has announced that the National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as a treatment for Fabry disease in adults.

© Getty Images

Q&A: The potential of immuno-oncology - a view from the R&D department

By Isabel Cameron

Cancer immunotherapy, more commonly known as immuno-oncology, continues to gather momentum. As a rapidly evolving field, ongoing research and advancements are coming together to expand the number of available treatments, many of which are showing incredible...

© Getty Images

J&J’s Akeega FDA approval to heat up PARP battle

By Isabel Cameron

The FDA recently granted approval for Johnson & Johnson’s (J&J) Akeega, a novel first-in-class combination tablet treatment for adults with breast cancer gene (BRCA)-positive, metastatic castration-resistant prostate cancer (mCRPC).

© Getty Images

Genprex bags FDA orphan drug designation for lung cancer therapy

By Isabel Cameron

Genprex has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead candidate, Reqorsa immunogene therapy (quaratusugene ozeplasmid), for the treatment of small cell lung cancer (SCLC).

© Getty Images

Epsilogen completes first-ever IgE antibody clinical trial

By Isabel Cameron

Epsilogen, a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, has published phase 1 data from the first ever clinical trial of an IgE antibody therapeutic in Nature Communications.

© Getty Images

First patient dosed in Enterome’s metastatic colon cancer trial

By Isabel Cameron

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases, has announced that the first patient has been dosed in its phase 1/2 trial evaluating EO4010.

Follow us

Webinars